Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Generics UK

- PMLiVE

NICE backs Lundbeck’s alcohol dependence drug Selincro

Alcoholics in England to have access to once-daily drug

- PMLiVE

Lundbeck’s desmoteplase flunks phase III stroke trial

No better than placebo at improving disability symptoms

- PMLiVE

Abbott offers up to $495m for Russia’s Veropharm

Acquisition will add to its generics portfolio

- PMLiVE

Teva restructures to stengthen unit identities

First major change at Israeli firm since Erez Vigodman’s appointment as CEO

- PMLiVE

Lundbeck agrees $658m deal to buy Chelsea Therapeutics

Acquisition boosts Danish firm's neurology profile and presence in US

European Commission launches mHealth consultation

May lead to policy action by 2015

- PMLiVE

Teva launches first generic of GSK’s Lovaza in US

Will have six months of marketing exclusivity for copy of cardiovascular drug

- PMLiVE

Sun Pharma offers $4bn for Ranbaxy

Follows period of manufacturing problems at Daiichi-owned Indian generics company

eHealth not up to speed in Europe

Less than one in three doctors email their patients and just 10 per cent hold online consultations

- PMLiVE

Abilify Maintena launches in Europe

Schizophrenia treatment is a key product to help Lundbeck replace lost Cipralex sales

EU flag

European Commission sets out HIV/Aids action plan

Says two-year programme proves HIV/Aids remains an EU health policy priority

- PMLiVE

Generic for Lilly’s Evista in US ‘within a month’

Teva to launch copy of osteoporosis drug

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links